4th Sep 2015 05:26
LONDON (Alliance News) - AstraZeneca PLC late on Thursday said the US Food and Drug Administration has approved its Brilinta tablets at a new 60 miligram dose to be used in patients with a history of heart attacks beyond the first year of treatment.
The FTSE 100 drugmaker said that with the expanded indication Brilinta is now approved as a treatment for reducing the rate of cardiovascular death, myocardial infarction and strokes in patients suffering with acute coronary syndrome of a history of heart attacks.
"We know that patients remain at risk beyond the first year after their heart attack. Today?s approval is an important milestone that underscores the role Brilinta can play in reducing the risk of a subsequent cardiovascular event for patients both in the acute setting and in the longer term," said Elisabeth Björk, vice president and head of cardiovascular and metabolic diseases within the global medicines development team at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca